David RosePartner at Mischon de Reya
David is Head of the Patents Group at Mishcon de Reya and a highly experienced IP litigator. Recently recognised as the UK IP Practitioner of the Year at the 2020 Annual Managing IP EMEA Awards, he is one of only a small number of lawyers in the UK who have taken both patent and trade mark cases to the Court of Justice of the European Union. In the patent sphere, David advises on patent infringement, validity and ownership disputes, the scope of protection of SPCs and disputes over standard essential patents (SEPs) including their licensing on FRAND terms (principally for implementers). He also has considerable experience advising on "clearing the way" strategies in relation to pharmaceutical patents. Recent cases include acting for Lupin in its successful application to revoke Gilead's SPC for the HIV treatment Truvada® following hearings before the Grand Chamber of the Court of Justice of the EU and the Court of Appeal. Additional high profile patent actions include: HTC v Gemalto; Napp v Sandoz; ratiopharm v Alza; Arrow Generics v Merck; Cairnstores v Astra Zeneca; and Servier v Lupin.
David is listed in the Legal 500 IP "Hall of Fame", is ranked as a leading individual in Chambers (IP, life sciences and patent litigation), IAM Patent 1000 (patents and life sciences), Who's Who Legal (patents, life sciences and trade marks), and is recognised as one of World Trademark Review's "Global Leaders". Recent commentary from the directories includes: "outstanding experience in this arena makes him a force of nature in the courtroom" (IAM Patent 100); "tough as nails... a 'natural litigator' who is 'experienced and aggressive" (World Trademark Review); "a real client's lawyer, always very tenacious in looking after their interests…He is good to work with and gets the best out of his team." and "has impeccable judgement on strategic matters" (Chambers)